Skip to main content

Advertisement

Table 1 Overview of all PD-L1 studies in IBC and their key findings. NACT neo-adjuvant chemotherapy, IHC immunohistochemistry, TMA tissue microarray, TC tumour cell, IC immune cell, N+ lymph node-positive disease, pCR pathological complete response, NR not reported, OS overall survival, DFS disease-free survival, sTIL stromal tumour-infiltrating lymphocytes, ER oestrogen receptor, T/NB tumour/normal breast ratio, TN triple negative

From: Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression

First author (year, country) No. Population Detection method AB clone Cutoff for PD-L1+ Positivity rate Associated clinical and pathological variables Associated outcome variables
He et al., [17] (2018, USA) 68 Post NACT
TN: 19/65
IHC
TMA [3]
28-8 ≥ 1% TC 25/68 (36.8%) / Worse OS
(P = 0.042)
Arias-Pulido et al. [16] (2018, Algeria) 221 Pre NACT
TN: 44/221
IHC
TMA [2]
SP142 ≥ 5% TC and IC TC: 18/221 (8.1%) IC: 146/221 (66.1%) TC: N+, CD20+ TIL, pCR
IC: grade 3, CD20+ TIL
IC: better DFS
(P = 0.035)
Reddy et al. [18] (2017, USA) 14 Pre NACT
TN: -
IHC
Biopsy
NR NR (TC) 3/14 (21.4%) NR NR
Hamm et al. [19] (2016, USA) 12 Pre NACT
TN: -
IHC
Biopsy
E1LN3 H-score
(TC and IC)
TC: 4/12 (33.3%)
IC: 8/12 (66.7%)
NR NR
Bertucci et al. [15] (2015, France) 112 Pre NACT
TN: 28/112
mRNA / T/NB ≥ 2 42/112 (37.5%) ER negativity, basal and HER2+ subtype, cytotoxic T cell response, pCR /
Discovery cohort (Belgium) 105 Pre NACT
TN: 23/105
IHC
Biopsy
SP142 ≥ 1% tumour area (TC and IC) TC: 2/105 (1.9%)
IC: 45/105 (42.9%)
IC: sTIL, pCR /
Validation cohort (France) 62 Pre NACT
TN: 12/62
IHC
Biopsy
SP142 ≥ 1% tumour area (TC and IC) TC: 0/62 (0%)
IC: 24/62 (38.7%)
IC: sTIL /